Increased systemic exposure w/ inhibitors of hepatic uptake transporter OATP1B1 (eg, rifampin, ciclosporin) & efflux transporter MRP2 (eg, ritonavir). Risk of increase in serum K or creatinine (in heart failure patients) w/ other agents that block the renin-angiotensin system, K-sparing diuretics (eg, spironolactone, triamterene, amiloride), K supplements or K-containing salt substitutes, or drugs that may increase K levels (eg, heparin). Possible deterioration of renal function, including possible acute renal failure (in patients who are elderly, vol-depleted (including those on diuretic therapy), or w/ compromised renal function) w/ NSAIDs including selective COX-2 inhibitors. Attenuated antihypertensive effect w/ NSAIDs including selective COX-2 inhibitors. Reversible increase in serum lithium conc. Increased risk of hypotension, hyperkalemia & decreased renal function w/ other agents acting on the renin-angiotensin system eg, ACE inhibitors, ARBs or aliskiren.
Sign Out
